Indrani joined Samsara BioCapital as a Senior Director Project and Portfolio Management in the fall of 2022. Prior to Samsara, Indrani was the Head of PPM at an Arrive Bio, a start-up applying in-vivo target screening with machine learning to age-related diseases. Before Arrive, Indrani spent over nine years at Gilead Sciences. She was the lead PM on the Hepatitis B Cure and Hepatitis D Programs and managed 7 programs across early and late-stage development. She joined Gilead as an Associate Scientist in the viral immunology group working on innate immune targets and Treg biology. From 2000-2004, Indrani worked at Maxygen Inc. in Redwood City as a research assistant in early drug discovery in the Protein Pharmaceuticals Division.
Indrani graduated with an MA in Molecular Cellular & Developmental Biology from University of Colorado at Boulder in 2004, and an MS in Molecular Biology from University of Wyoming in 2000. She has a BSc in Microbiology from Nizam Collage, Hyderabad, India.